Premium
Proteins that specifically recognize cisplatin‐damaged DNA: a clue to anticancer activity of cisplatin
Author(s) -
Zlatanova Jordanka,
Yaneva Julia,
Leuba Sanford H.
Publication year - 1998
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.12.10.791
Subject(s) - cisplatin , dna , chemistry , anticancer drug , biochemistry , structural similarity , dna damage , drug , biology , genetics , pharmacology , chemotherapy
Cisplatin, but not its trans geometric isomer, is a potent anticancer drug whose biological activity is a consequence of the formation of covalent adducts between the platinum compound and certain bases in DNA. Two classes of proteins have recently been identified that bind preferentially to damaged sites: proteins that specifically recognize those sites as a first step in their repair, and those that bind to such sites by virtue of structural similarity between the modified DNA and their own natural binding sites. Both classes of proteins may be involved, perhaps in opposing ways, in the cytotoxic effect of the drug.